SCHEMBL3350274

SCHEMBL3350274

O=C(O)NCCC(O)NCc1ccc(OC(F)(F)F)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 5/20 0.46
NR1H4 Q96RI1 1/20 0.46
PPARA Q07869 5/20 0.46
PPARG P37231 2/20 0.46
SCN9A Q15858 1/20 0.44
LTA4H P09960 1/20 0.44
HTR2C P28335 3/20 0.43
VNN1 O95497 1/20 0.42
SCN8A Q9UQD0 1/20 0.42
PLA2G1B P04054 1/20 0.41
MAPT P10636 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ATG4B Q9Y4P1 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
PPARD Q03181 2/20 0.41
PTGER4 P35408 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3351538 0.85 MAPK14 (0.53) PPARAPPARGSCN9AVNN1PPARD
SCHEMBL3351114 0.83 KCNH2 (0.45) EPHX2PPARAPPARGPPARD
SCHEMBL3357892 0.83 CASR (0.54) SMN1; SMN2
SCHEMBL6635990 0.80 EPHX2 (0.61) EPHX2NR1H4PPARAPPARGLTA4H
SCHEMBL5330973 0.80 SCN8A (0.52) EPHX2NR1H4PPARAPPARGLTA4H
SCHEMBL3356473 0.79 SMN1; SMN2 (0.49) SMN1; SMN2
SCHEMBL3356519 0.78 PPARG (0.46) EPHX2PPARGSCN9AVNN1
SCHEMBL3353131 0.74 MEN1 (0.47) SMN1; SMN2CA2
SCHEMBL3355242 0.73 BCHE (0.49) PLA2G1BMAPTATG4B
SCHEMBL28386258 0.71 EPHX1 (0.52) EPHX2NR1H4PPARAPPARGSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP EPHX2 3436/4885NR1H4 2268/4885PPARA 3166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.